In its most recent quarter ending March 2026, Rani Therapeutics advanced its clinical pipeline, notably initiating a Phase 1 trial for RT-114 using its novel oral delivery platform. Strategic partnerships with Chugai Pharmaceutical and ProGen continue to bolster development and regulatory efforts. However, Nasdaq has notified the company of its non-compliance with minimum bid price requirements, introducing potential listing risks if unresolved by November 2026. Rani's vertically integrated manufacturing and proprietary RaniPill technology remain central to its business model targeting injectable biologic replacement, although lack of commercial revenue keeps financial sustainability under scrutiny.